Bone Marrow Transplant Rejection – Pipeline Review, H1 2017 – Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Industries

The Bone Marrow Transplant Rejection – Pipeline Review, H1 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Immune Disorders Drugs, Immunosuppressive Drugs, Pharmaceuticals Markets.

Bone Marrow Transplant Rejection – Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection – Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 26, 16, 1, 35, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 13 and 3 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
– The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to Buy:

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read more and order at Bone Marrow Transplant Rejection – Pipeline Review, H1 2017

Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016 – Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Industries

The Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016 Report has been published. It provides updated in 2018 year analysis of industries from Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Markets.

Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016

Summary

Our clinical trial report, “Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016" provides an overview of Occlusive Arterial Disease (OAD) clinical trials scenario. This report provides top line data relating to the clinical trials on Occlusive Arterial Disease (OAD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

Read more and order at Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2016

Microbe – Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Industries

The Microbe Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals Markets.

Microbe, a brand–new, general microbiology textbook intended for upper–division undergraduate and beginning graduate courses, is an exciting introduction to the world of microbes. With a distinct ecological and evolutionary orientation, Microbe invites readers to partake of the most current advances in the field. Written by prominent scientists with practical teaching, textbook writing, and research experience, this new textbook will engage students in the learning process with its clear, reader–friendly style and unique perspective of the field. Microbe is paradigm–driven rather than fact–driven. Key concepts are illustrated by inspiring examples that convey the excitement of the field. This is not a compendium of facts, but rather a textbook in the older, traditional sense: a book that can be used for studying rather than for looking up factual information. The book is divided into seven sections covering the most pertinent information related to the study of microbes, including microbial activity; structure and function; growth, inheritance, physiology, and diversity; and biological interactions. Each chapter concludes with thought–provoking study questions, for which answers are listed in the back of the book. Microbe is accompanied by a dedicated Web site featuring links to additional information and animation and video clips related to material covered in the book. Sidebars throughout the text guide readers to designated links that are easily accessed through the Microbe homepage. The Web site will be monitored and updated regularly by the authors.

Read more and order at Microbe

Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1 – Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Industries

The Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Pharmaceuticals, Respiratory Drugs Markets.

Dr. Jon Koff has assembled and expert team of authors of the topic of Cystic Fibrosis. Articles include: Epidemiology and Pathobiology, Genetics and genetic medicine in Cystic Fibrosis, Innate and Adaptive Immunity in Cystic Fibrosis, Microbiome in Cystic Fibrosis, Diagnostic Testing in Cystic Fibrosis, Treating Pseudomonas in Cystic Fibrosis, Diagnosis of Adult Patients with Cystic Fibrosis, Transition from Pediatrics to Adult Care, Lung Transplant in Cystic Fibrosis, and more!

Read more and order at Cystic Fibrosis, An Issue of Clinics in Chest Medicine. The Clinics: Internal Medicine 37-1

Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017 – Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Industries

The Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017 Report has been published. It provides updated in 2018 year analysis of industries from Drugs by Therapeutic Area, Liver and Kidney Disorders Drugs, Pharmaceuticals Markets.

Hepatitis C Virus (HCV) Protease Inhibitor-Mechanism of action Insights, 2017 provides comprehensive insights of the ongoing therapeutic research and development across Hepatitis C Virus (HCV) Protease Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hepatitis C Virus (HCV) Protease Inhibitor by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the Report:

  • The report provides a snapshot of the pipeline development for the Hepatitis C Virus (HCV) Protease Inhibitor
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Hepatitis C Virus (HCV) Protease Inhibitor
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Hepatitis C Virus (HCV) Protease Inhibitor
  • The report also covers the dormant and discontinued pipeline projects related to the Hepatitis C Virus (HCV) Protease Inhibitor

Reasons to Buy:

  • Establish comprehensive understanding of the pipeline activity across this Hepatitis C Virus (HCV) Protease Inhibitor to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Hepatitis C Virus (HCV) Protease Inhibitor therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Note: Please allow up to 48 hours for delivery of this report after payment has been made.

Read more and order at Hepatitis C Virus (HCV) Protease Inhibitor – Pipeline Insights, 2017

Food Hypersensitivity. Diagnosing and Managing Food Allergies and Intolerance – Allergy Drugs, Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Industries

The Food Hypersensitivity. Diagnosing and Managing Food Allergies and Intolerance Report has been published. It provides updated in 2018 year analysis of industries from Allergy Drugs, Drugs by Therapeutic Area, Immune Disorders Drugs, Pharmaceuticals Markets.

Specialist dietitians, Isabel Skypala and Carina Venter assemble a team of expert authors to separate fact from fiction and provide the reader with an authoritative and practical guide to handling the difficult issue of food hypersensitivity.

Offering advice for treating children and adults in one book and written in an accessible style, the book is split into three main sections:

  • Diagnosis
  • Dietary management
  • Allergy prevention and nutritional considerations

This exceptional volume is essential reading for all dietitans, nutritionists, paediatricians, allergists, family practitioners, GPs, practice nurses, health visitors and other health care professionals who work in this area or have an interest in food allergy. The book is also an excellent reference for undergraduate and postgraduate students studying allergy, immunology or nutrition and dietetics. Libraries in all universities and research establishments where nutrition, dietetics, food science, medicine and health sciences are studied and taught should have copies of this important work on their shelves

Read more and order at Food Hypersensitivity. Diagnosing and Managing Food Allergies and Intolerance

US Market Report for Psoriasis Immunology Drugs 2018 – MedCore – Dermatological Drugs, Drugs by Therapeutic Area, Pharmaceuticals, Psoriasis Drugs Industries

The US Market Report for Psoriasis Immunology Drugs 2018 – MedCore Report has been published. It provides updated in 2018 year analysis of industries from Dermatological Drugs, Drugs by Therapeutic Area, Pharmaceuticals, Psoriasis Drugs Markets.

General Report Contents

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

The typical life cycle of a healthy skin cell is about one month, but in people with psoriasis this process may take just a few days. This rapid overproduction leads to the build-up of skin cells because they do not have time to fall off. In most cases psoriasis can be diagnosed during the skin examination by dermatologist. In some cases, psoriasis can look like eczema and may require additional diagnostic tests, including biopsy, blood tests and X-rays.

Treating options vary depending on the level of pain and swelling. Non-steroidal anti-inflammatory drugs (ibuprofen, Motrin or Advil) or naproxen (Aleve) are used as initial treatment. In more severe cases disease modifying anti-rheumatic drugs (DMARDs) may be prescribed. DMARDs include sulfasalazine, methotrexate, cyclosporine and leflunomide. Other options are biologic medications, including HUMIRA® (adalimumab), Enbrel® (etanercept), SIMPONI® (golimumab), CIMZIA® (certolizumab), STELARA® (ustekinumab) and REMICADE® (infliximab) that are indicated for the both arthritis and skin psoriasis treatment.

The most recent developments include Cosentyx® (secukinumab), a biologic injection manufactured by Novartis for the treatment of psoriatic arthritis and launched in 2015. Cosentyx® is currently approved in more than 75 countries for the treatment of moderate-to-severe plaque psoriasis. The product is available in the European Union countries, Japan, Switzerland, Australia, the United States and Canada.

Read more and order at US Market Report for Psoriasis Immunology Drugs 2018 – MedCore

Atrial Tachycardia. Volume 11. Clinical Approaches To Tachyarrhythmias – Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Industries

The Atrial Tachycardia. Volume 11. Clinical Approaches To Tachyarrhythmias Report has been published. It provides updated in 2018 year analysis of industries from Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Markets.

In the course of understanding the mechanism and therapy of atrial tachycardia, important distinctions are emerging in electrophysiological evaluations of various atrial arrhythmias, which come under scrutiny in this latest addition to the CATA Series. New diagnostic tools and more accurate understandings of atrial anatomy allow finer detection of the clinical and electrocardiographic presentation of cardiac arrhythmias. With invasive electrical mapping, intracardiac ultrasound imaging, and catheter ablation, multiple distinct arrhythmic mechanisms can be recognized and the substrate treated for a variety of tachycardiac conditions.

The aim of the Clinical Approaches to Tachyarryhthmias series is to update the physician, cardiologist, and all those responsible for the the care of patients with cardiac arrhythmias. This comprehensive review offers cardiologists and electrocardiographers the latest knowledge in what is an evolving field, as innovative techniques drive the ability to diagnose and treat different tachycardia types with new interventional approaches.

Read more and order at Atrial Tachycardia. Volume 11. Clinical Approaches To Tachyarrhythmias

Postpartum Hemorrhage (PPH) Treatment Devices Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023 – Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Industries

The Postpartum Hemorrhage (PPH) Treatment Devices Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023 Report has been published. It provides updated in 2018 year analysis of industries from Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Markets.

The global postpartum hemorrhage (PPH) treatment devices market grow at an impressive CAGR of 12.1%, and is projected to contribute $769 million by 2021. Postpartum hemorrhage is defined as excessive loss of blood within first 24 hours following childbirth. This heavy loss of blood can occur in both, that is, after C-section, as well as, during or after a natural birth. Postpartum hemorrhage can prove to be lethal if the patient are not taken care of properly. Postpartum hemorrhage is the leading cause of maternal deaths majorly in low income countries. It causes around one quarter of all maternal deaths in the world. According to doctors, poor uterine contractions are the leading cause of the postpartum hemorrhage. Most of the products in the PPH treatment devices market globally aim towards healing the uterine conditions and the problem of contraction. It is a chronic condition that claims millions of women’s life every year. There are various factors affecting the postpartum hemorrhage treatment devices market such as rising prevalence of postpartum hemorrhage cases; increasing awareness of peoples regarding postpartum hemorrhage; increasing postpartum hemorrhage risk factors; technological advancement in medical device field; and, so on.

Postpartum hemorrhage can also be treated by using drugs like Methergine, Cytotec, Pitocin, Misoprostol, Oxytocin, Sytocinon, Carboprost, and so on. These drugs can cure postpartum hemorrhage only to a certain extent. People might get scared of postpartum hemorrhage surgeries, so as an alternative, they uses anti-hemorrhage drugs to minimize the loss of blood flow. This alternative acts as a barrier in the growth of global postpartum hemorrhage (PPH) treatment devices market.

The global postpartum hemorrhage (PPH) treatment devices market is segmented into type and regional outlook. On the basis of type, market is divided into uniject prefilled injection system, non-pneumatic anti-shock garment (NASG), uterine balloon temponade. The uterine balloon temponade is further subdivided into Foley catheters, condom catheters and others. The uterine balloon temponade is having the largest market share in this segment, and its dominance is expected to continue in the near future. The major reason that drives this segments are high effectiveness, low cost, and easy availability of these devices. In regional outlook, market is divided into North America, Europe, Asia Pacific and Rest of the World. North America dominates the postpartum hemorrhage treatment devices market in terms of revenue. North America accounted for around 35% of global market share in 2015. The major factor for the dominance of the North American market is rising prevalence of postpartum hemorrhage; increasing cases of pregnancies associated with medical complications; high hospital delivery rates; increasing awareness among health care professionals and patients, etc. Maternal mortality rate is increasing rapidly in the U.S. The U.S dominates the postpartum hemorrhage market in the North America region. Reason being, easy access to medical devices; highly structured healthcare systems; various favorable reimbursement policies from private and public sector health insurance firms. Europe is the second largest postpartum hemorrhage (PPH) treatment devices market, with major countries like U.K, Germany Switzerland, Spain, Portugal, Italy, Belgium and others accounting for major share in global postpartum hemorrhage (PPH) treatment devices market in the Europe region. Factors that are pushing the European region upward is increasing number of cases related to postpartum hemorrhage; easy availability of treatment of devices; technological advanced products; and, growing healthcare sector, etc. The United Kingdom has the majority of share in the Europe region, due to the rise of maternal mortality rate from postpartum hemorrhage in the region. Apart from that high awareness level among health providers, availability of medical products, increasing government’s initiatives are some other major factors. Asia Pacific is the third largest, and one of the fastest growing global postpartum hemorrhage (PPH) treatment devices market. Emerging markets in the region are expected to have immense market growth potential. The factors such as highly susceptible patient population, improvement in healthcare infrastructure and increasing prevalence of postpartum hemorrhage are the major factors to boost the Asia Pacific region. As per WHO, postpartum hemorrhage accounts for around 30% of all maternal deaths in Africa and Asia. The proportion of postpartum hemorrhage attributable maternal deaths vary substantially across countries in these regions. Apart from that, prevalence rate of anemia among women in developing countries such as China, Hong Kong and India is around 60% this complicates the cases of patients experiencing postpartum hemorrhage. Currently, approximately 65% of the deliveries in developing countries are managed by skilled health care professionals in order to reduce the risk of postpartum hemorrhage. Thus, these factors are cumulatively expected to drive the postpartum hemorrhage treatment devices market in the region. The Rest of the world region is showing attractive growth rate in global postpartum hemorrhage (PPH) treatment devices market. The major factors are increasing penetration of international players in the region, improving financial stability and high prevalence rate of postpartum hemorrhage. Brazil is the major country in this region.

Some of the major market players are Utah Medical Products, Inc.; Cook Medical, Inc.; Bactiguard AB; 3rd Stone Design, Inc.; C.R. Bard, Inc.; Program for Appropriate Technology in health (PATH); Teleflex Incorporated; ZOEX NIASG, etc. Development of new products, Acquisition, mergers and expansions are the key strategies adopted by the market players to sustain in the market.


Note:
Please allow up to 72 hours for delivery.

Read more and order at Postpartum Hemorrhage (PPH) Treatment Devices Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Atrial Fibrillation – Market Insights & Drugs Sales Forecast (AF) – 2020 – Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Industries

The Atrial Fibrillation – Market Insights & Drugs Sales Forecast (AF) – 2020 Report has been published. It provides updated in 2018 year analysis of industries from Cardiovascular Drugs, Drugs by Therapeutic Area, Pharmaceuticals Markets.

The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Key Coverage and Benefits:

– The report will help in developing business strategies by understanding the trends shaping and driving the global Atrial Fibrillation (AF) market.
– Identifying patient populations in the global Atrial Fibrillation (AF) market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation (AF) therapeutics in each of the markets covered.
– To understand the future market competition in the global Atrial Fibrillation (AF) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

– Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.
– Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
– The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
– It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Note*: This report requires 2 business days to complete.

Read more and order at Atrial Fibrillation – Market Insights & Drugs Sales Forecast (AF) – 2020